Skip to main content
. 2020 Apr 28;11(17):1478–1492. doi: 10.18632/oncotarget.27539

Figure 5. PI3K activity compensates for PIM inhibition in PIK3CA mutant breast cancer.

Figure 5

(A) MDA-MB-175 (PIK3CA wt), MDA-MB-453 (PIK3CA mutant, HER2+), and T-47D (PIK3CA mutant) cells were treated with the indicated concentrations of abemaciclib for 4 h and analyzed by western blot. (B) MDA-MB-453 cells were treated with the combination of PI3K inhibitor BYL719 (0.3 µM) and abemaciclib or PIM447 for 4 h and analyzed by western blot.